FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant\, Metastatic Castration-Resistant Prostate Cancer (mCRPC)